TY - JOUR
T1 - Tracheal regeneration using an artificial trachea
T2 - A multicenter clinical trial:
AU - Kishimoto, Yo
AU - Tateya, Ichiro
AU - Yamashita, Masaru
AU - Mizuta, Masanobu
AU - Kitamura, Morimasa
AU - Suehiro, Atsushi
AU - Nakamura, Tatsuo
AU - Omori, Koichi
N1 - Publisher Copyright:
© 2017, Japan Society for Head and Neck Cancer. All rights reserved.
PY - 2017
Y1 - 2017
N2 - A tracheal resection is sometimes required because of malignancies or stenosis due to traumas or inflammatory diseases, and the consequent tracheal defect causes cosmetic and functional problems. Although early closure of the stoma is expected, the closure of a huge stoma is still challenging. We have developed an artificial trachea according to the concept of in situ tissue engineering in the past few decades, aiming to establish a safe and easy procedure for tracheal reconstruction. The long-term safety and efficacy of our in situ regeneration-inducing artificial trachea composed of a porcine collagen sponge and polypropylene framework have been confirmed by previous non-clinical and clinical studies. In order to obtain approval for our in situ regeneration-inducing artificial trachea as a new medical device under Japan’s Pharmaceutical and Medical Device Law, we are now running a multi-institutional, investigator-initiated clinical trial of tracheal reconstruction using our artificial trachea. Patients with a stoma unable to be reconstructed with existing treatment options, or with malignancies affecting no less than half of the tracheal cartilage as well as three tracheal rings, will be included in this trial. When the safety and efficacy of the artificial trachea are proven with this trial, we plan to apply for approval of the artificial trachea as a new medical device.
AB - A tracheal resection is sometimes required because of malignancies or stenosis due to traumas or inflammatory diseases, and the consequent tracheal defect causes cosmetic and functional problems. Although early closure of the stoma is expected, the closure of a huge stoma is still challenging. We have developed an artificial trachea according to the concept of in situ tissue engineering in the past few decades, aiming to establish a safe and easy procedure for tracheal reconstruction. The long-term safety and efficacy of our in situ regeneration-inducing artificial trachea composed of a porcine collagen sponge and polypropylene framework have been confirmed by previous non-clinical and clinical studies. In order to obtain approval for our in situ regeneration-inducing artificial trachea as a new medical device under Japan’s Pharmaceutical and Medical Device Law, we are now running a multi-institutional, investigator-initiated clinical trial of tracheal reconstruction using our artificial trachea. Patients with a stoma unable to be reconstructed with existing treatment options, or with malignancies affecting no less than half of the tracheal cartilage as well as three tracheal rings, will be included in this trial. When the safety and efficacy of the artificial trachea are proven with this trial, we plan to apply for approval of the artificial trachea as a new medical device.
UR - http://www.scopus.com/inward/record.url?scp=85038418209&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038418209&partnerID=8YFLogxK
U2 - 10.5981/jjhnc.43.367
DO - 10.5981/jjhnc.43.367
M3 - Article
AN - SCOPUS:85038418209
SN - 1349-5747
VL - 43
SP - 367
EP - 371
JO - Japanese Journal of Head and Neck Cancer
JF - Japanese Journal of Head and Neck Cancer
IS - 3
ER -